Table 1.
Demographic and clinical characteristics.
| MSD PBSCT, n (%) |
UCBT, n (%) | p value | |
|---|---|---|---|
| N | 104 | 41 | |
| Age | 0.06 | ||
| Age, median (range) | 54 (23–74) | 50 (19–69) | |
| Gender | 0.74 | ||
| Male | 69 (66%) | 26 (63%) | |
| Diagnosis | |||
| Acute leukemia | 57 (55%) | 29 (71%) | |
| Chronic leukemia (CML/CLL) | 4 (4%) | 2 (5%) | |
| Lymphoma | 21 (20%) | 4 (10%) | |
| Other | 22 (21%) | 6 (15%) | |
| Donor type | |||
| Matched sibling | 104 (100%) | 0 (0%) | |
| sUCBT | 0 (0%) | 9 (22%) | |
| dUCBT | 0 (0%) | 32 (78%) | |
| Conditioning regimen | 0.02 | ||
| Myeloablative with total body irradiation | 35 (34%) | 24 (59%) | |
| Myeloablative without total body irradiation | 3 (3%) | 1 (2%) | |
| Reduced intensity conditioning | 66 (63%) | 16 (39%) | |
| HCT- Comorbidity Index | 0.75 | ||
| Low risk: 0 | 41 (39%) | 19 (46%) | |
| Intermediate risk: 1–2 | 31 (30%) | 11 (27%) | |
| High risk: 3+ | 32 (31%) | 11 (27%) | |
| Days from HCT to cGvHD | |||
| Days (median range) | 218 (88–1111) | 224 (110–903) | |
| GvHD prophylaxis | <0.01 | ||
| CNI + MTX | 50 (48%) | 0 (0%) | |
| CNI + MMF | 54 (52%) | 33 (80%) | |
| Sirolimus+MMF | 0 (0%) | 8 (20%) | |
| CMV, Recepient/Donor (R/D) | |||
| R+/D+ | 29 (28%) | 0 (0%) | |
| R+/D− | 26 (25%) | 26 (63%) | |
| R−/D− | 34 (33%) | 15 (37%) | |
| R−/D+ | 15 (14%) | 0 (0%) | |
| HLA match | |||
| 8/8 HLA matched | 104 (100%) | 0 (0%) | |
| sUCBT | 0 (0%) | 9 (22%) | |
| 4/6 HLA matched | 2 (22%) | ||
| 5/6 HLA matched | 5 (56%) | ||
| 6/6 HLA matched | 2 (22%) | ||
| dUCBT | 0 (0%) | 32 (78%) | |
| 4/6 + 4/6 HLA matched | 9 (28%) | ||
| 4/6 + 5/6 HLA matched | 5 (16%) | ||
| 4/6 + 6/6 HLA matched | 0 (0%) | ||
| 5/6 + 5/6 HLA matched | 10 (31%) | ||
| 5/6 + 6/6 HLA matched | 6 (19%) | ||
| 6/6 + 6/6 HLA matched | 2 (6%) | ||
| Prior aGvHD by grade | <0.01 | ||
| No aGvHD | 47 (45%) | 6 (15%) | |
| Grade 1 | 6 (6%) | 2 (5%) | |
| Grade 2 | 30 (29%) | 12 (29%) | |
| Grade 3 | 15 (14%) | 17 (41%) | |
| Grade 4 | 6 (6%) | 4 (10%) | |
| Karnofsky score at cGvHD diagnosis | 0.75 | ||
| <90 at cGvHD diagnosis | 28 (27%) | 10 (24%) | |
| Cumulative incidence of cGvHD | 104/340 (31%) | 41/391(10%) | |
| cGvHD onset | <0.01 | ||
| De-Novo | 47 (45%) | 6 (15%) | |
| Quiescent | 34 (33%) | 23 (56%) | |
| Progressive | 23 (22%) | 12 (29%) | |
| cGvHD type | 0.58 | ||
| Classic | 71 (68%) | 26 (63%) | |
| Overlap | 33 (32%) | 15 (37%) | |
| cGvHD global severity at diagnosis | 0.01 | ||
| Mild | 12 (12%) | 12 (29%) | |
| Moderate | 59 (57%) | 23 (56%) | |
| Severe | 33 (32%) | 6 (15%) | |
| Numbers of organs at cGvHD diagnosis | 0.08 | ||
| 1 or 2 | 49 (47%) | 26 (63%) | |
| 3+ | 55 (53%) | 15 (37%) | |
| Platelets count at cGvHD diagnosis | 0.34 | ||
| <100 × 10e9/L | 25 (24%) | 13 (32%) | |
| ≥100 × 10e9/L | 79 (76%) | 28 (68%) | |
| Eosinophil count at cGvHD diagnosis | 0.05 | ||
| <0.7 × 10e9/L | 79 (76%) | 37 (90%) | |
| ≥0.7 × 10e9/L | 25 (24%) | 4 (10%) | |
| Lymphocyte count at cGvHD diagnosis | 0.63 | ||
| <0.8 × 10e9/L | 27 (26%) | 12 (29%) | |
| ≥0.8–5.3 × 10e9/L | 77(74%) | 29 (71%) | |
| cGvHD treatment | 0.33 | ||
| Systemic | 26 (25%) | 13 (32%) | |
| Topical | 7 (7%) | 5 (12%) | |
| Both (topical & systemic) | 71 (68%) | 23 (56%) |
CML chronic myelogenous leukemia, CLL chronic lymphocytic leukemia, UCBT umbilical cord blood transplant, sUCBT single UCBT, dUCBT double UCBT, HCT-CI Hematopoietic Cell Transplantation - comorbidity index, CNI calcineurin inhibitor, MTX Methotrexate, MMF mycophenolate mofetil, CMV cytomegalovirus, HLA human leukocyte antigen, MSD PBSCT matched sibling donor peripheral blood stem cell transplant, cGvHD chronic graft-versus-host disease, aGvHD acute graft-versus-host disease.